Merck KGaA Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application
- Details
- Category: Merck Group
Merck KGaA announced that its US affiliate received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS).
Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
- Details
- Category: Pfizer
Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher's disease.
"Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS
- Details
- Category: Bristol-Myers Squibb
The National AIDS Fund (NAF) and Bristol-Myers Squibb Company (NYSE: BMY) announced their intention to launch "Positive Charge", a new multiyear initiative aimed at helping to break down the barriers that prevent people living with HIV from receiving HIV care, treatment and necessary support. The initiative is slated to launch in January 2010.
Bayer Starts Phase III Trial with Florbetaben
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, is progressing with the development of florbetaben to support Alzheimer diagnosis. On the occasion of the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the company announced the enrollment of first patients in an international clinical Phase III trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid deposition in the brain.
Bayer starts pivotal Phase III trial with Florbetaben
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, is progressing with the development of florbetaben to support Alzheimer diagnosis. On the occasion of the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the company announced the enrollment of first patients in an international clinical Phase III trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid deposition in the brain.
Novartis gains rights to two oral targeted investigational therapies
- Details
- Category: Novartis
Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effective treatment options.
Lundbeck initiates clinical phase II trials with Lu AE58054
- Details
- Category: Lundbeck
H. Lundbeck A/S announced the initiation of a multi-centre, placebo-controlled, fixed-dose study of Lu AE58054 as add-on to donepezil in patients with moderate Alzheimer's disease. The clinical phase II study is planned to enrol approximately 270 patients.
More Pharma News ...
- FDA Grants IBsolvMIR Orphan Drug designation in the treatment of diabetes patients in the U.S.
- Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
- Merck KGaA to Expand Research and Development Presence in China
- Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA®
- FDA Advisory Committee Finds Data Support SPIRIVA® HandiHaler®
- AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor)
- GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction